Skip to main content
Clinical Trials/NCT04828421
NCT04828421
Completed
Not Applicable

The Effect of Probiotic Supplementation on Cognitive and Emotional Functions in Healthy Elderly Subjects: a Randomized, Double-blind, Cross-over and Controlled Trial

Universidad de Almeria2 sites in 1 country36 target enrollmentJuly 17, 2020
ConditionsHealthy

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Healthy
Sponsor
Universidad de Almeria
Enrollment
36
Locations
2
Primary Endpoint
Change from Baseline Depression at 10 weeks
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

This study evaluates the cognitive and emotional effects of probiotics in healthy elderly patients.

Detailed Description

Gut microbiota (GM) has focused as an important target for emotional and cognitive diseases, moreover in a population that show an altered GM such as elderly population as age-related changes. Several studies have shown that ageing alter GM, both in diversity and integrity. Probiotics have demonstrated that correct or prevent age-related dysbiosis, in order to reduce or prevent intestinal permeability and associated inflammation, inhibit the generation of harmful and/or toxic metabolites, as well as promote the production of beneficial bacterial components. The aim of this study is to assess the effectiveness of a multiprobiotic formulation as a therapeutic strategy to attenuate the emotional and cognitive decline associated with ageing in healthy adults over 55 years of age. The hypothesis is that administration of a multi-species probiotic for 10 weeks will slow and/or ameliorate the decline in emotional and cognitive function inherent to senescence.

Registry
clinicaltrials.gov
Start Date
July 17, 2020
End Date
April 30, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Pablo Román López

Principal Investigator, Vicedean of Nursing

Universidad de Almeria

Eligibility Criteria

Inclusion Criteria

  • be aged 55 years or over,
  • voluntarily agree to participate in the study in accordance with the Helsinki declaration,
  • not be participating in another study that could interfere with the results.

Exclusion Criteria

  • suffer from any serious mental illness other than depression and anxiety,
  • score below 10 on the Mini-Mental State Examination (MMSE) (severe cognitive impairment)
  • be using medications that affect cognition,
  • taking anti-inflammatory drugs, antipsychotics, antibiotics and/or anxiolytics,
  • have a serious illness (e.g. cancer, Parkinson's or Alzheimer's).

Outcomes

Primary Outcomes

Change from Baseline Depression at 10 weeks

Time Frame: Before and after treatment (10 weeks)

The Beck Depression Inventory. Score range: 0-63.

Change from Baseline General Cognitive Status at 10 weeks

Time Frame: Before and after treatment (10 weeks)

Mini-Mental State Examination. Score range: 0-35

Change from Baseline Motor impulsivity or inhibitory response at 10 weeks

Time Frame: Before and after treatment (10 weeks)

Go/No-Go task

Change from Baseline Planning Ability at 10 weeks

Time Frame: Before and after treatment (10 weeks)

Tower of London test

Change from Baseline Problem-solving ability at 10 weeks

Time Frame: Before and after treatment (10 weeks)

Wisconsin Card Sorting test

Change from Baseline Visual Attention at 10 weeks

Time Frame: Before and after treatment (10 weeks)

Trail Making Test

Change from Baseline Selective attention, cognitive flexibility and response inhibition at 10 weeks

Time Frame: Before and after treatment (10 weeks)

Stroop task

Change from Baseline Anxiety at 10 weeks

Time Frame: Before and after treatment (10 weeks)

The State-Trait Anxiety Inventory. Score range: 20-80

Change from Baseline Working Memory at 10 weeks

Time Frame: Before and after treatment (10 weeks)

Digits task, Corsi task

Change from Baseline Choice impulsivity or impulsive decision-making at 10 weeks

Time Frame: Before and after treatment (10 weeks)

Iowa Gambling Task

Secondary Outcomes

  • Change from Baseline Body Composition at 10 weeks(Before and after treatment (10 weeks))
  • Change from Baseline Gastrointestinal Symptom at 10 weeks(Before and after treatment (10 weeks))
  • Change from Baseline Food Habits at 10 weeks(Before and after treatment (10 weeks))
  • Change from Baseline Sleep Quality at 10 weeks(Before and after treatment (10 weeks))
  • Change from Baseline Stool Consistency at 10 weeks(Before and after treatment (10 weeks))
  • Change from Baseline Perceived Stress at 10 weeks(Before and after treatment (10 weeks))
  • Change from Baseline Alcohol Use at 10 weeks(Before and after treatment (10 weeks))
  • Change from Baseline Physical Activity at 10 weeks(Before and after treatment (10 weeks))

Study Sites (2)

Loading locations...

Similar Trials